Pharmaceutical Executive July 9, 2024
Acquisition of Morphic is aimed to enhance treatment options for inflammatory bowel disease and expand Lilly’s gastroenterology portfolio.
Eli Lilly and Company has reached a definitive agreement to acquire Morphic Holding, Inc., a biopharmaceutical company specializing in oral integrin therapies for chronic diseases. The deal includes MORF-057, Morphic’s lead drug candidate that is currently in a Phase II study for ulcerative colitis and Crohn disease. Classified as a selective, oral small molecule inhibitor of α4β7 integrin, the company stated that the treatment has significant potential in improving outcomes and expanding treatment options for patients.1
“Oral therapies could open up new possibilities for earlier intervention in diseases like ulcerative colitis, and also provide the potential for combination therapy to help patients...
Today's Sponsors
Today's Sponsor